On March 5, 2020, the Commissioner of the U.S. Food and Drug Administration (FDA) released a statement describing the agency’s continued evaluation of cannabidiol (CBD) products and signaling issuance of
Continue Reading FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products
CBD Products
What We Learned From FDA’s Public Hearing On Cannabis*
By Christopher Van Gundy & Sarah Blitz on
Posted in FDA, Regulatory Compliance
*This article was originally posted in Law360 on June 4, 2019.
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial plant.
Continue Reading What We Learned From FDA’s Public Hearing On Cannabis*